Pre-exposure rabies booster vaccinations: A literature review

Developments in Biologicals

Volumn 125, Issue , 2006, Pages 205-215

  Morris, J ^a   Crowcroft, N S ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RABIES VACCINE; VIRUS ANTIBODY;

ANIMAL; BAT; BLOOD; CONFERENCE PAPER; DOSE RESPONSE; FEMALE; HUMAN; IMMUNIZATION; LEGAL ASPECT; MALE; PRACTICE GUIDELINE; RABIES VIRUS; UNITED KINGDOM; VACCINATION; VIROLOGY; VIRUS INFECTION;

ANIMALS; ANTIBODIES, VIRAL; CHIROPTERA; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GREAT BRITAIN; GUIDELINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; LYSSAVIRUS; MALE; RABIES VACCINES; RHABDOVIRIDAE INFECTIONS; VACCINATION;

EID: 33745520847     PISSN: 14246074     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (17)

1. Fooks AR, Brookes SM, Johnson N, McElhinney LM, Hutson AM: European bat lyssaviruses: an emerging zoonosis. Epidemiol Infect 2003; 131: 1029-1039.
2. WHO Expert Consulation on Rabies. First Report. Geneva, World Health Organization, 2004 (WHO technical report series, 931).
3. th July 2005.
4. HPA. First serotine bat from southern England found to be positive for EBLV1 antibodies. Commun Dis Rep CDR Wkly [serial online] 2005 [cited 3 June 2005], 15 (22): news. Available at 〈http://www.hpa. org.uk/cdr/archives/ archive05/News/news2205.htm#bats〉.
5. Preliminary results of study into bat rabies (European bat lyssavirus) in England. Press release 215/05. London: DEFRA, 21 May 2005. Available at 〈http://www.defra.gov.uk/news/2005/050521a.htm〉.
6. th July 2005.
7. Strady A, Lang J, Lienard M, Blondeau C, Jaussaud R, Plotkin SA: Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998; 177: 1290-1295.
8. Klietmann W, Klietmann B, Cox J, Charbonnier C: Effectiveness and tolerance of pre- and postexposure treatment with purified inactivated rabies vaccine prepared on Vero cell line. Vaccine 1988; 6: 39-43.
9. Dreesen DW, Fishbein DB, Kemp DT, Brown J: Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunisation. Vaccine 1989; 7: 397-400.
10. Simani S et al: Evaluation of the effectiveness of preexposure rabies vaccination in Iran. Arch Iranian Med 2004; 7 (4): 251-255.
11. Ajjan N, Pilet CH: Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 1989; 7: 125-128.
12. Sabchareon A et al: A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis 1999; 29: 141-149.
13. Sabchareon A et al: Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunisations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998; 17(11): 1001-1007.
14. Lang J et al: Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomised, double-blind trial with purified Vero-cell rabies vaccine (PVRV). Biologicals 1998; 26: 299-308.
15. Picot N et al: Booster effect of a new chromato graphically purified Vero-cell rabies vaccine (CPRV): immunogenicity of a single or double injection. Trans R Soc Trop Med Hyg 2001; 95: 342-344.
16. Bernard KW et al: Preexposure immunisation with intradermal human diploid cell rabies vaccine. JAMA 1987; 257 (8): 1059-1063.
17. Briggs DJ et al: Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults. Vaccine 1996; 14 (14): 1361-1365.